UPLOAD Filing
AIxCrypto Holdings, Inc.
Date: Sept. 23, 2025 · CIK: 0001460702 · Accession: 0000000000-25-010354
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290306
Letter
Re: Qualigen Therapeutics, Inc. Registration Statement on Form S-1 Filed September 16, 2025 File No. 333-290306 Dear Kevin Richardson II:
September 23, 2025
Kevin Richardson II Interim Chief Executive Officer Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, CA 92008
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ross Carmel, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 23, 2025 Kevin Richardson II Interim Chief Executive Officer Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, CA 92008 Re: Qualigen Therapeutics, Inc. Registration Statement on Form S-1 Filed September 16, 2025 File No. 333-290306 Dear Kevin Richardson II: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ross Carmel, Esq. </TEXT> </DOCUMENT>